Nabi Biopharmaceuticals (NASDAQ: NABI)
Rockville, MD 20852 (Map) Phone: 301-770-3099
Fax: 301-770-3097
Toll Free: 800-685-5579
http://www.nabi.com
Overview
Nabi Biopharmaceuticals nabs human antibodies to make pharmaceutical therapies. The biotechnology company develops vaccine products for conditions in a number of areas, including infectious diseases and nicotine addiction. Its primary candidate, the NicVAX vaccine for nicotine addition, works by stimulating antibodies (immune-system proteins) that reduce cravings. NicVAX is being developed in partnership with GlaxoSmithKline (GSK), which has an option to license worldwide marketing rights to the vaccine. The company had also been developing a vaccine designed to fight hospital-acquired infections, PentaStaph, but it has divested that vaccine candidate.
Sample OverviewKey Numbers from Hoover's UK
Key financials for Nabi Biopharmaceuticals (NASDAQ: NABI)
| Company Type | Public (NASDAQ: NABI) |
|---|---|
| Fiscal Year-End | December |
| 2010 Sales (mil.) | £22.6 |
| 1-Year Sales Growth | 233.7% |
| 2010 Net Income (mil.) | £0.6 |
| 2010 Employees | 35 |
| 1-Year Employee Growth | (16.7%) |
Key People from Hoover's UK
Key people and executives for Nabi Biopharmaceuticals (NASDAQ: NABI)
| Chairman | Geoffrey F. Cox (Subscribers see complete biographies -- view sample)
|
|---|---|
| President, CEO, Acting CFO, and Director | Raafat E. F. Fahim |
| Manager Investor Relations and Corporate Communications | Gregory Fries |
Top Competitors from Hoover's UK
Top competitors of Nabi Biopharmaceuticals (NASDAQ: NABI)
There are 13 competitors for Nabi Biopharmaceuticals; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
More Industry InformationRankings from Hoover's UK
See how Nabi Biopharmaceuticals (NASDAQ: NABI) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
